Cincor Pharma, Inc.

CINCCIK 0001868734 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K filed Mar 22, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:No prior 10-KFull-doc fallback

Full filing:tone -0.0162

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Cincor Pharma, Inc.

Name	Roles	Filings
5am Opportunities I, L.P.	10% Owner	2
5am Partners VI, LLC	10% Owner	2
5am Ventures VI, L.P.	10% Owner	2
Healy James	Director10% Owner	2
Kalb Michael Wayne	Officer	2

Showing 6-10 of 40

Per pagePrevPage 2 of 8Next

All filings

31 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jan 30, 2023	Freeman Mason Chief Medical Officer	AGrant	40,000	-	-
Jan 30, 2023	Kalb Michael Wayne EVP & Chief Financial Officer	AGrant	177,000	-	-
Jan 30, 2023	Pearce Catherine Chief Operating Officer	AGrant	15,000	-	-
Jan 30, 2023	De Garidel Marc Chief Executive Officer · Director	AGrant	200,000	-	-
Jan 19, 2023	Pearce Catherine Chief Operating Officer	FTax	3,997	$28.75	$114,914

Showing 11-15 of 31

Per pagePrevPage 3 of 7Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value